13F Data
13F filer · CIK 1757283

ANDERA PARTNERS

PARIS, I0 · filing since Q4 2025 · last filing Oct 16, 2026
Reported value
$175.7M
$-30.8M vs prior
Positions
7
New / sold out
0 / 1
Added / reduced
0 / 1
Turnover
0.0%
buys $0 · sells $21.1M
Top-10 weight
100.0%

Biggest buys vs Q2 2026

No new or increased positions this quarter.

Biggest sells vs Q2 2026

ChangeSecurityShares changeChange %Est. trade value
ReducedEVOMMUNE INC-1,294,628-93.0%$-10.7M
Sold outABIVAX SA-78,125-100.0%$-10.4M

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2025: $176.6MQ1 2026: $176.9MQ2 2026: $206.5MQ3 2026: $175.7M
Q4 2025Q3 2026

Holdings · Q3 2026

#SecuritySharesValueWeight
1KESTRA MED TECHNOLOGIES LTDSHS2,728,679$77.2M43.94%
2MINERALYS THERAPEUTICS INCCOM1,591,917$40.0M22.77%
3AVALYN PHARMACEUTICALS INCCOM SHS929,824$26.5M15.08%
4AGOMAB THERAPEUTICS NVSPONSORED ADS1,538,702$17.1M9.72%
5INVENTIVA SAADS3,633,181$13.4M7.63%
6EVOMMUNE INCCOM SHS97,362$804.2K0.46%
7NYXOAH S ASHS522,057$720.4K0.41%